Tokai Pharmaceuticals Inc. (NASDAQ:TKAI)’s share price was up 2.6% during trading on Thursday . The stock traded as high as $5.56 and last traded at $5.47, with a volume of 87,999 shares trading hands. The stock had previously closed at $5.33.

Several equities analysts have recently commented on TKAI shares. Bank of America Corp. started coverage on Tokai Pharmaceuticals in a report on Wednesday, April 6th. They set a “buy” rating and a $16.00 target price for the company. Janney Montgomery Scott reaffirmed a “buy” rating and set a $12.00 target price on shares of Tokai Pharmaceuticals in a report on Tuesday, April 12th. Finally, BMO Capital Markets began coverage on Tokai Pharmaceuticals in a report on Monday, April 11th. They set an “outperform” rating and a $11.00 target price for the company. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Tokai Pharmaceuticals has an average rating of “Buy” and a consensus price target of $18.00.

The firm’s market capitalization is $117.77 million. The stock has a 50-day moving average of $5.81 and a 200 day moving average of $6.32.

Tokai Pharmaceuticals (NASDAQ:TKAI) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by $0.01. Analysts anticipate that Tokai Pharmaceuticals Inc. will post ($2.00) EPS for the current year.

Tokai Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.